FDA panel to discuss Merck's bezlotoxumab

FDA's Antimicrobial Drugs Advisory Committee will meet June 9 to discuss a BLA from Merck & Co. Inc. (NYSE:MRK) for bezlotoxumab ( MK-6072) to prevent Clostridium difficile infection recurrence. The candidate is under Priority Review, with a PDUFA date of July 23. ...